Dopamine dysregulation syndrome in Parkinson’s disease: a systematic review of published cases
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: Dopamine dysregulation syndrome (DDS) is an uncommon complication of the treatment of Parkinson's disease, characterised by addictive behaviour and excessive use of dopaminergic medication. DDS may frequently go unrecognised or misdiagnosed. We aimed to clarify current understanding of presentation, risk factors, comorbidities and management of DDS. METHODS: Case reports were identified through a systematic search of databases (PubMed, Embase) with the following terms: dopaminergic dysregulation syndrome, hedonistic homeostatic dysregulation, dopamine/levodopa addiction. RESULTS: We reviewed 390 articles, identifying 98 cases of DDS. Early-onset Parkinson's disease (67%) and male gender (83%) were common. DDS presented with significant physical and social impairment, actions to enable or prevent detection of overuse, as well as mood, anxiety and motor fluctuations. All DDS cases met DSM-V (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition) substance use disorder criteria. Past substance and psychiatric history was present in 15.3% and 10.2% of cases. Comorbid impulse control disorders (61%), psychosis (32%) and panic attacks (14%) were common. A large variety of management strategies were used; only 56% of cases resolving. Sodium valproate was successful in 5/5 cases. The response to deep brain stimulation varied. CONCLUSIONS: Given the functional impairment, medical and psychiatric consequences and the difficulties of treatment, early identification of DDS should be a priority.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Di Chiara, G., & Imperato, A. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.14.5274 · Cited by 4,733
Systematic review of levodopa dose equivalency reporting in Parkinson's disease
Tomlinson, C. L., Stowe, R., Patel, S., Rick, C., Gray, R., & Clarke, C. E. (2010) · Movement Disorders · doi:10.1002/mds.23429 · Cited by 4,219
Electrical Stimulation of the Subthalamic Nucleus in Advanced Parkinson's Disease
Limousin, P., Krack, P., Pollak, P., Benazzouz, A., Ardouin, C., Hoffmann, D., & Benabid, A.-L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810153391603 · Cited by 1,853
DSM-5 criteria for substance use disorders: recommendations and rationale
Hasin, D. S., O’Brien, C. P., Auriacombe, M., Borges, G., Bucholz, K., Budney, A., Compton, W. M., Crowley, T., Ling, W., Petry, N. M., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.12060782 · Cited by 1,622
Rascol, O., Brooks, D. J., Korczyn, A. D., De Deyn, P. P., Clarke, C. E., & Lang, A. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005183422004 · Cited by 1,539
The psychology and neurobiology of addiction: an incentive–sensitization view
Robinson, T. E., & Berridge, K. C. (2000) · Addiction · doi:10.1046/j.1360-0443.95.8s2.19.x · Cited by 1,507
Barone, P., Antonini, A., Colosimo, C., Marconi, R., Morgante, L., Avarello, T. P., Bottacchi, E., Cannas, A., Ceravolo, G., Ceravolo, R., et al. (2009) · Movement Disorders · doi:10.1002/mds.22643 · Cited by 1,445
Sex differences in impulsivity: A meta-analysis.
Cross, C. P., Copping, L. T., & Campbell, A. (2011) · Psychological Bulletin · doi:10.1037/a0021591 · Cited by 866
Are men at greater risk for Parkinson's disease than women?
Wooten, G. F. (2004) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2003.020982 · Cited by 695
Dyskinesias and motor fluctuations in Parkinson's disease
Schrag, A., & Quinn, N. (2000) · Brain · doi:10.1093/brain/123.11.2297 · Cited by 600
Giovannoni, G. (2000) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.68.4.423 · Cited by 587
Compulsive drug use linked to sensitized ventral striatal dopamine transmission.
Evans, A. H., Pavese, N., Lawrence, A. D., Tai, Y. F., Appel, S., Doder, M., Brooks, D. J., Lees, A. J., & Piccini, P. (2006) · Annals of Neurology · doi:10.1002/ana.20822 · Cited by 473
Ageing, neurodegeneration and Parkinson's disease
Hindle, J. V. (2010) · Age and Ageing · doi:10.1093/ageing/afp223 · Cited by 430
Subthalamic stimulation in Parkinson’s disease: restoring the balance of motivated behaviours
Lhommée, E., Klinger, H., Thobois, S., Schmitt, E., Ardouin, C., Bichon, A., Kistner, A., Fraix, V., Xie, J., Aya Kombo, M., et al. (2012) · Brain · doi:10.1093/brain/aws078 · Cited by 296
Compulsive use of dopamine replacement therapy in Parkinson's disease: reward systems gone awry?
Lawrence, A. D., Evans, A. H., & Lees, A. J. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00529-5 · Cited by 282
Dopamine Dysregulation Syndrome: An Overview of its Epidemiology, Mechanisms and Management
OʼSullivan, S. S., Evans, A. H., & Lees, A. J. (2009) · CNS Drugs · doi:10.2165/00023210-200923020-00005 · Cited by 265
Lim, S.-Y., O’Sullivan, S. S., Kotschet, K., Gallagher, D. A., Lacey, C., Lawrence, A. D., Lees, A. J., O’Sullivan, D. J., Peppard, R. F., Rodrigues, J. P., et al. (2009) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2008.12.010 · Cited by 240
Factors influencing susceptibility to compulsive dopaminergic drug use in Parkinson disease
Evans, A. H., Lawrence, A. D., Potts, J., Appel, S., & Lees, A. J. (2005) · Neurology · doi:10.1212/01.wnl.0000184487.72289.f0 · Cited by 210
Prevalence and clinical features of hedonistic homeostatic dysregulation in Parkinson's disease
Romana Pezzella, F., Colosimo, C., Vanacore, N., Di Rezze, S., Chianese, M., Fabbrini, G., & Meco, G. (2005) · Movement Disorders · doi:10.1002/mds.20288 · Cited by 154
Psychosis in Parkinson’s Disease: Epidemiology, Pathophysiology, and Management
Chang, A., & Fox, S. H. (2016) · Drugs · doi:10.1007/s40265-016-0600-5 · Cited by 144
"Panic attacks" in Parkinson's disease. A long-term complication of levodopa therapy.
Vázquez, A., Jiménez-Jiménez, F. J., Ruiz, P., & García-Urra, D. (1993) · PubMed · Cited by 142
Moum, S. J., Price, C. C., Limotai, N., Oyama, G., Ward, H., Jacobson, C., Foote, K. D., & Okun, M. S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0029768 · Cited by 137
Subthalamic nucleus stimulation and compulsive use of dopaminergic medication in Parkinson's disease
Eusébio, A., Witjas, T., Cohen, J., Fluchère, F., Jouve, É., Régis, J., & Azulay, J.-P. (2013) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2012-302387 · Cited by 132
Eskow Jaunarajs, K. L., Angoa-Perez, M., Kuhn, D. M., & Bishop, C. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.06.007 · Cited by 130
“Panic attacks” in Parkinson's disease: A long-term complication of levodopatherapy
Vázquez, A., Jiménez-Jiménez, F. J., García-Ruiz, P., & García-Urra, D. (2009) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1993.tb04068.x · Cited by 128
Cilia, R., Siri, C., Canesi, M., Zecchinelli, A., Gaspari, D. D., Natuzzi, F., Tesei, S., Meucci, N., Mariani, C., Sacilotto, G., et al. (2013) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2012-303988 · Cited by 88
Bearn, J., Evans, A. H., Kelleher, M., Turner, K., & Lees, A. J. (2004) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2004.06.005 · Cited by 66
Alcohol Consumption, Types of Alcohol, and Parkinson’s Disease
Liu, R., Guo, X., Park, Y., Wang, J., Huang, X., Hollenbeck, A., Blair, A., & Chen, H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066452 · Cited by 64
Solla, P., Cannas, A., Floris, G., Orofino, G., Costantino, E., Boi, A., Serra, C., Marrosu, M. G., & Marrosu, F. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2011.02.002 · Cited by 60
Fenu, S., Wardas, J., & Morelli, M. (2009) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e32833109a0 · Cited by 56
Compulsive use of dopaminergic drug therapy in Parkinson's disease: Reward and anti‐reward
Evans, A. H., Lawrence, A. D., Cresswell, S. A., Katzenschlager, R., & Lees, A. J. (2010) · Movement Disorders · doi:10.1002/mds.22898 · Cited by 51
Dopaminergic dysregulation syndrome in Parkinson's disease
Katzenschlager, R. (2011) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2011.07.012 · Cited by 44
Hicks, C. W., Pandya, M., Itin, I., & Fernandez, H. H. (2011) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2011.03.003 · Cited by 43
Addiction-Like Manifestations and Parkinson's Disease: A Large Single Center 9-Year Experience
Limotai, N., Oyama, G., Go, C. L., Bernal, O., Ong, T. L., Moum, S. J., Bhidayasiri, R., Foote, K. D., Bowers, D., Ward, H. E., et al. (2011) · International Journal of Neuroscience · doi:10.3109/00207454.2011.633722 · Cited by 40
Valproate as a treatment for dopamine dysregulation syndrome (DDS) in Parkinson’s disease
Sriram, A., Ward, H. E., Hassan, A., Iyer, S. S., Foote, K. D., Rodriguez, R. L., McFarland, N. R., & Okun, M. S. (2012) · Journal of Neurology · doi:10.1007/s00415-012-6669-1 · Cited by 40
Relationship between age and subtypes of psychotic symptoms in Parkinson's disease
Kızıltan, G., Özekmekçi, S., Ertan, S., Ertan, T., & Erginöz, E. (2007) · Journal of Neurology · doi:10.1007/s00415-006-0388-4 · Cited by 39
Linazasoro, G. (2008) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3181634ea6 · Cited by 25
Stefanis, C., & Reisby, N. (1993) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1993.tb05356.x · Cited by 24
Dopamine dysregulation syndrome in Parkinson's disease patients: From reward to penalty
Bonci, A., & Singh, V. (2006) · Annals of Neurology · doi:10.1002/ana.20878 · Cited by 15
Cited by
Parkinson’s disease: etiopathogenesis and treatment
Jankovic, J., & Tan, E. K. (2020) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2019-322338 · Cited by 1,169
Ferroptosis in Parkinson's disease: Molecular mechanisms and therapeutic potential
Ding, X.-S., Gao, L., Han, Z., Eleuteri, S., Shi, W., Shen, Y., Song, Z.-Y., Su, M., Yang, Q., Qu, Y., et al. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102077 · Cited by 193
“Pseudo-syndromes” associated with Parkinson disease, dementia, apathy, anxiety, and depression
Weiss, H. D., & Pontone, G. M. (2019) · Neurology Clinical Practice · doi:10.1212/cpj.0000000000000644 · Cited by 21
Metadata
- Authors
- Warren, N., O’Gorman, C., Lehn, A., & Siskind, D.
- Venue
- Journal of Neurology, Neurosurgery & Psychiatry
- Publisher
- BMJ
- Published
- 2017-10-10
- Volume
- 88
- Issue
- 12
- Pages
- 1060-1064
- ISSN
- 0022-3050 (ISSN-L)
- 1468-330X
- OpenAlex
- W2763198934
- Cited by
- 172
- References
- 41
- FWCI
- 3.17
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.